Artiva Biotherapeutics, Inc.

Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.

ARTV | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 5505 MOREHOUSE DRIVE, 92121 SAN DIEGO
Website:: https://www.artivabio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing allogeneic, off-the-shelf natural killer (NK) cell-based therapies. The company's mission is to create effective, safe, and broadly accessible treatments for patients with autoimmune diseases and cancer. Its lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy designed for use in combination with monoclonal antibodies. AlloNK® is currently being evaluated in multiple clinical trials for B-cell driven autoimmune diseases, including rheumatoid arthritis and Sjögren’s disease, as well as for certain cancers. Artiva aims to address the limitations of existing cell therapies, such as complex manufacturing and severe toxicities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Artiva Biotherapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Artiva Biotherapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Artiva Biotherapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Arcellx, Inc. Engineering controllable cell therapies for cancer and autoimmune diseases.	United States of America	ACLX
Arctic Bioscience Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.	Norway	ABS
ArcticZymes Technologies Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.	Norway	AZT
Arcturus Therapeutics Holdings Inc. Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.	United States of America	ARCT
Arcus Biosciences, Inc. A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.	United States of America	RCUS
Arcutis Biotherapeutics, Inc. Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.	United States of America	ARQT
ARDELYX, INC. Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.	United States of America	ARDX
ARECOR THERAPEUTICS PLC Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.	United Kingdom	AREC
argenx SE Develops first-in-class antibody therapies for severe autoimmune diseases.	Netherlands	1AE
ARGENX SE Develops antibody-based therapies for severe autoimmune diseases, including its lead drug VYVGART.	United States of America	ARGX